XML 53 R39.htm IDEA: XBRL DOCUMENT v3.23.1
Note 2 - Revenue - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
 12 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Mar. 31, 2021
Revenues $ 219,080 $ 184,335 $ 133,937
Consumables [Member] | Transferred at Point in Time [Member]      
Revenues 117,841 91,808 63,009
Hardware and Software [Member] | Transferred at Point in Time [Member]      
Revenues 62,679 57,614 44,019
Service [Member]      
Revenues 38,560 34,913 26,909
Service [Member] | Transferred at Point in Time [Member]      
Revenues 38,560 34,913 26,909
Operating Segments [Member]      
Revenues 219,080 184,335 133,937
Operating Segments [Member] | Clinical Genomics [Member]      
Revenues [1] 62,299 32,840 0
Operating Segments [Member] | Sterilization and Disinfection Control [Member]      
Revenues [1] 64,609 59,044 53,119
Operating Segments [Member] | Biopharmaceutical Development [Member]      
Revenues [1] 47,365 45,579 33,892
Operating Segments [Member] | Calibration Solutions [Member]      
Revenues [1],[2] 44,807 46,872 46,926
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Clinical Genomics [Member]      
Revenues 43,374 22,271 0
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Sterilization and Disinfection Control [Member]      
Revenues 55,605 50,311 45,869
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Biopharmaceutical Development [Member]      
Revenues 15,800 15,551 13,942
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Calibration Solutions [Member]      
Revenues 3,062 3,675 3,198
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Clinical Genomics [Member]      
Revenues 13,347 6,726 0
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Sterilization and Disinfection Control [Member]      
Revenues 692 700 505
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Biopharmaceutical Development [Member]      
Revenues 22,079 21,651 13,545
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Calibration Solutions [Member]      
Revenues [2] 26,561 28,537 29,969
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Clinical Genomics [Member]      
Revenues 5,578 3,843 0
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Sterilization and Disinfection Control [Member]      
Revenues 8,312 8,033 6,745
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Biopharmaceutical Development [Member]      
Revenues 9,486 8,377 6,405
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Calibration Solutions [Member]      
Revenues [2] $ 15,184 $ 14,660 $ 13,759
[1] Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.
[2] Revenues in the Clinical Genomics division represent transactions subsequent to the Agena Acquisition on October 20, 2021.